SCHEMBL12879439

SCHEMBL12879439

c1cnc(-c2cnc(C3CCNCC3)s2)nc1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CHRNB2 P17787 1/20 0.48
CHRNA4 P43681 1/20 0.48
MAP4K3 Q8IVH8 3/20 0.45
MEN1 O00255 1/20 0.42
KMT2A Q03164 1/20 0.42
TLR9 Q9NR96 1/20 0.41
TLR8 Q9NR97 1/20 0.41
TLR7 Q9NYK1 1/20 0.41
HPGDS O60760 2/20 0.40
HTR1A P08908 6/20 0.36
SLC6A2 P23975 6/20 0.36
SLC6A4 P31645 6/20 0.36
SLC6A3 Q01959 2/20 0.35
NPC1 O15118 1/20 0.35
RAB9A P51151 1/20 0.35
SLC18A3 Q16572 1/20 0.34
SIGMAR1 Q99720 1/20 0.34
HTR2C P28335 2/20 0.34
HRH3 Q9Y5N1 1/20 0.34
CHRM4 P08173 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12879440 0.83 MAP4K3 (0.39) CHRNB2CHRNA4MAP4K3MEN1KMT2A
SCHEMBL4677044 0.79 CHRNB2 (0.53) CHRNB2CHRNA4MAP4K3MEN1KMT2A
SCHEMBL17151793 0.74 MAP4K3 (0.48) CHRNB2CHRNA4MAP4K3TLR9TLR8
SCHEMBL27911963 0.74 CHRNB2 (0.51) CHRNB2CHRNA4MAP4K3MEN1KMT2A
SCHEMBL27742532 0.73 CHRNB2 (0.50) CHRNB2CHRNA4MAP4K3TLR9TLR8
SCHEMBL14314252 0.73 MEN1 (0.42) CHRNB2CHRNA4MAP4K3MEN1KMT2A
SCHEMBL14129191 0.72 TLR9 (0.42) CHRNB2CHRNA4MAP4K3MEN1KMT2A
SCHEMBL20809193 0.72 CHRNB2 (0.46) CHRNB2CHRNA4MAP4K3MEN1KMT2A
Hydrochloric Acid SCHEMBL20135187 0.71 CHRNB2 (0.46) CHRNB2CHRNA4MAP4K3MEN1KMT2A
SCHEMBL30926191 0.71 CHRNB2 (0.48) CHRNB2CHRNA4MAP4K3MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8546404-B2 Compounds that are ERK inhibitors MERCK SHARP & DOHME (US) 2013-10-01 US disclosed
US-8546404-B2 Compounds that are ERK inhibitors MERCK SHARP & DOHME (US) 2013-10-01 US disclosed
EP-2155722-B1 POLYCYCLIC INDAZOLE DERIVATIVES AND THEIR USE AS ERK INHIBITORS FOR THE TREATMENT OF CANCER MERCK SHARP & DOHME (US) 2013-08-14 EP disclosed
US-20110038876-A1 HETEROCYCLIC COMPOUNDS AND USE THEREOF AS ERK INHIBITORS SCHERING CORPORATION 2011-02-17 US disclosed
US-20110038876-A1 HETEROCYCLIC COMPOUNDS AND USE THEREOF AS ERK INHIBITORS SCHERING CORPORATION 2011-02-17 US disclosed
US-20090118284-A1 Novel compounds that are ERK inhibitors MERCK SHARP & DOHME LLC 2009-05-07 US disclosed
US-20090118284-A1 Novel compounds that are ERK inhibitors MERCK SHARP & DOHME LLC 2009-05-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110038876-A1 HETEROCYCLIC COMPOUNDS AND USE THEREOF AS ERK INHIBITORS MAPK1, MAPK4, MAPK10 CHRNB2 4757/4885CHRNA4 4748/4885MAP4K3 20/4885
US-20090118284-A1 Novel compounds that are ERK inhibitors MAPK1, MAPK4, MAPK10 CHRNB2 4383/4885CHRNA4 4559/4885MAP4K3 24/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.